Once the DEA has collected the necessary data, the DEA Administrator, by authority of the Attorney General, requests from the HHS a scientific and medical evaluation and recommendation as to whether the drug or other substance should be controlled or removed from control. This request is sent to the Assistant Secretary of Health of the HHS. Then, the HHS solicits information from the Commissioner of the Food and Drug Administration and evaluations and recommendations from the National Institute on Drug Abuse, and on occasion, from the scientific and medical community at large. The Assistant Secretary, by authority of the Secretary, compiles the information and transmits back to the DEA a medical and scientific evaluation regarding the drug or other substance, a recommendation as to whether the drug should be controlled, and in what schedule it should be placed.
Combined preparations . A number of trials have been carried out with implants containing two hormones. The combination of an oestrogen with an anabolic steroid, or with progesterone, has met with the greatest responses. Synovex-S has consistently increased gain as well as FCE, with responses averaging about 20% and 17% respectively (20, 21, 22, 34, 35, 36, 37, 42, 43, 44, 45, 46, 47, 48). Hexoestrol + TBA (usually 30 or 45 mg hexoestrol + 300 mg TBA) has resulted in marked increases in gain (24, 25, 26, 29, 49, 50, 51, 52, 53), of the order of 30% and in FCE (25, 49, 50, 51, 53) of the order of 20%. Oestradiol-17β + TBA (20/140 mg) has given similar results (27, 28, 37, 54, 55), as has Zeranol + TBA (36/300 mg), also recently tested (27, 37, 38, 39, 40, 41, 56).